Drug Information

General Information
Drug ID
DR00250
Drug Name
Oseltamivir
Synonyms
(-)-oseltamivir; (3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid; 4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; Agucort; Agucort (TN); Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; GS 4104; GS-4104; GS4104; OTV; Oseltamivir (INN); Oseltamivir [INN:BAN]; Oseltamivirum; Ro-64-0796; Ro-640796; Tamiflu (*Phosphate salt 1:1*); Tamiflu (TN); Tamiflu-Free; Tamvir
Drug Type
Small molecular drug
Indication Influenza virus [ICD11: 1E30-1E32] Approved [1]
Therapeutic Class
Antiviral Agents
Structure
3D MOL 2D MOL
Formula
C16H28N2O4
Canonical SMILES
CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC
InChI
InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1
InChIKey
VSZGPKBBMSAYNT-RRFJBIMHSA-N
CAS Number
CAS 204255-11-8
Pharmaceutical Properties Molecular Weight 312.4 Topological Polar Surface Area 90.6
Heavy Atom Count 22 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
XLogP
1.1
PubChem CID
65028
PubChem SID
10292 , 103375662 , 104332669 , 117576917 , 118048381 , 124893596 , 126657793 , 126681234 , 126733879 , 134338002 , 135023115 , 135811666 , 137002940 , 137236650 , 140589553 , 14825762 , 14898934 , 151982861 , 152099920 , 152258534 , 160647368 , 160963546 , 164786722 , 164831566 , 165702338 , 174006818 , 175267600 , 176484257 , 179116828 , 184546341 , 185976796 , 196109901 , 211535901 , 223556618 , 43121870 , 46507602 , 49958481 , 50123365 , 53789667 , 57315247 , 58106749 , 626306 , 75193389 , 7980209 , 8034664 , 8189453 , 85789649 , 92309047 , 93166584 , 96024993
ChEBI ID
ChEBI:7799
TTD Drug ID
D0O5NK
DT(s) Transporting This Drug MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [2]
OAT1 Transporter Info Organic anion transporter 1 Substrate [3]
OAT3 Transporter Info Organic anion transporter 3 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
PEPT1 Transporter Info Peptide transporter 1 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data P-GP Transporter Info Km = 4.2 microM LLC-PK1 cells-MDR1 [4]
PEPT1 Transporter Info Km = 8590 microM Human cervical cancer cell line (Hela)-PEPT1 [5]
PEPT1 Transporter Info Km = 6540 microM Human enterocyte-like 2 cells (Caco-2)-PEPT1 [5]
References
1 Oseltamivir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21.
3 FDA Drug Development and Drug Interactions
4 Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61.
5 Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos. 2009 Aug;37(8):1676-81.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.